TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03811652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7247
Description: Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7247
Description: Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7247
Description: Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7247
Description: Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
Study: NCT03448380

Intervention type: DEVICE
Intervention: FreeStyle Libre Flash Glucose Monitoring System
Description: Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
Study: NCT05307926

Intervention type: DRUG
Intervention: PD-1 inhibitors
Description: For patients with PVTT, they received adjuvant therapy of PD1 (200mg intravenously every 3 weeks for a total of 18cycles) plus Lenvatinib (8mg orally once a day for 1 year) 2-4 weeks after surgery; for patients with other high-risk factors for recurrence, they PD-1(200mg intravenously every 3 weeks for a total of 9cycles) monotherapy 2-4 weeks after surgery.
Study: NCT00694967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 hydroxyprogesterone caproate
Description: Weekly 250mg intramuscular injections
Study: NCT03437200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, bolus fluorouracil 400 mg/m2, and infusional fluorouracil 1600 mg/m2 over 48 h), followed by 3 cycles of 2 weeks of FOLFOX without RT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, bolus fluorouracil 400 mg/m2, and infusional fluorouracil 1600 mg/m2 over 48 h), followed by 3 cycles of 2 weeks of FOLFOX without RT.
Study: NCT03331068

Intervention type: BEHAVIORAL
Intervention: online questionnaire of MAX-PC
Description: Scale measuring of the anxiety specific of prostate cancer, French version.
Study: NCT02008500

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo mouthwash
Description: 15 ml placebo mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Herbal Mouthwash
Description: 15 ml Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non Herbal Mouthwash
Description: 15 ml Non Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
Study: NCT01479803

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Puncture with fine needle aspiration under endoscopic ultrasonographic control
Description: Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control Passage in the same pancreatic mass of first EchoTip HD Procore then EchoTip 22 Gauge or vice versa according to the randomization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Puncture with fine needle aspiration under endoscopic ultrasonographic control
Description: Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control Passage in the same pancreatic mass of first EchoTip HD Procore then EchoTip 22 Gauge or vice versa according to the randomization
Study: NCT01418209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose 17-ß-estradiol with progesterone taper
Description: Low-dose 17-ß-estradiol oral (by mouth), 0.5 mg once per day for 8 (eight) weeks. 17-ß-estradiol is approved by the US Food and Drug Administration (FDA) and is indicated for the treatment of menopausal symptoms. ß is the Greek symbol for beta; the symbol and the word are used interchangeably. The 8 week estradiol treatment is followed by 14 days (2 weeks) of progesterone taper (as medroxy-progesterone 10 mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR
Description: Venlafaxine oral (by mouth) 37.5 mg once per day for 1 (one) week, then 75 mg once per day for 7 (seven) weeks. Venlafaxine XR should not be taken while also taking monoamine oxidase inhibitors (MAOIs). Venlafaxine XR is approved by the US Food and Drug Administration (FDA) for treatment of depression, generalized anxiety disorder, social anxiety disorder, and panic disorder, and is available by prescription. Venlafaxine XR is not FDA-approved for the treatment of hot flashes, although prior studies have indicated that it is useful for treating hot flashes and vasomotor symptoms. After the 8-week venlafaxine XR study treatment period, women will receive a tapering dose of venlafaxine XR 37.5 mg once per day for 14 days (2 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is an inactive pill that looks like the active medication.
Study: NCT00101101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Cell-Based Vaccine
Description: Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
Study: NCT01180738

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body weight supported treadmill training
Description: Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking on a treadmill using a body weight support system.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Overground walking training
Description: Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking overground.
Study: NCT02419846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend 10-20 minute PowerPoint presentation that will discuss prostate cancer facts, screening guidelines, risks, benefits, and consequences

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend 10-20 minute PowerPoint presentation that will discuss prostate cancer facts, screening guidelines, risks, benefits, and consequences

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: digital rectal examination
Description: Undergo digital rectal exam by a licensed healthcare professional. The results of this exam will be subjective as per clinician; however, will be coded as normal or abnormal. This is considered standard of care for prostate cancer screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-test administration
Description: 15 questions which test participants' knowledge of prostate cancer according to ACS guidelines. Questions will be multiple choices and true/false/unsure answers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-test administration
Description: 15 questions which test participants' knowledge of prostate cancer according to ACS guidelines. Questions will be multiple choices and true/false/unsure answers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Survey will be administered at the end of the program for participants to assess their experience

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Survey will be administered at the end of the program for participants to assess their experience

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen measurement
Description: PSA levels will be drawn and run as per institutional Laboratory standards. Criteria for referral and follow up will be assessed as per National Comprehensive Cancer Network (NCCN) guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post test administration
Description: Post test will include the same 15 questions as on the pretest to assess for improvement in knowledge and understanding

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post test administration
Description: Post test will include the same 15 questions as on the pretest to assess for improvement in knowledge and understanding
Study: NCT03494036

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule
Study: NCT05307926

Intervention type: PROCEDURE
Intervention: TACE
Description: Patients with high-risk factors for recurrence received 1 TACE about a month after surgery.
Study: NCT00258310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine 1000mg/day for one year

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery, chemotherapy and/or radiotherapy
Description: Surgery, chemotherapy and/or radiotherapy
Study: NCT00462241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chiropractic treatment
Description: Participants in the therapy group undergo a physical examination by an experienced, primary sector chiropractor, lasting up to one hour. The chiropractors choose an individual treatment strategy based on a combination of their findings, the patient history, and a standardized protocol reflecting routine practice. The standardized treatment protocol includes high velocity, low amplitude manipulation directed towards the thoracic and/or cervical spine in combination with any of the following: Joint mobilisation, soft tissue techniques, stretching, stabilising or strengthening exercises, heat or cold treatment, and advice. The protocol specifies up to ten treatment sessions of approximately 20 minutes, 1-3 times per week, or treatment until the patient is pain free. The chiropractors record the types of treatment rendered at sessions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Self-management
Description: Advice group: Advice is directed towards promoting self-management. The participants are told that their chest pain generally has a benign, self limiting course. The participants receive individual instructions regarding posture and two or three exercises aiming to increase spinal or muscle stretch based on clinical evaluation. They are advised to seek medical attention for re-evaluation (general physician, chest pain clinic or emergency department) in case of severe or unfamiliar chest pain. The session lasts on average 15 minutes. Further, the advice group is also asked not to seek any manual treatment for the next four weeks.
Study: NCT00474370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc
Description: One tablet of vicriviroc 30 mg once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet of placebo once daily.
Study: NCT00495716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acyclovir
Description: 800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acyclovir
Description: 400 mg acyclovir orally twice daily for 1 year
Study: NCT04519658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: CIN-107 tablets by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: CIN-107 tablets by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: CIN-107 tablets by mouth once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets by mouth once daily
Study: NCT02976896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
Study: NCT04246385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-OP Group
Description: Participants in the intervention group will attend one 1:1 session where one goal will be selected from their COPM results to focus on during the group, group expectations will be reviewed, caregivers will be invited, and questions answered. The group will run six sessions as supported by the literature (Chan, 2007; Lee, Fischer, Zera, Robertson, \& Hammel 2017).~Day Rehab CO-OP Group Curriculum Session Content~Introduction One on one session. COPM, introduction to group, education for caregiver. Session 1 Introduction to group and CO-OP approach, homework. Session 2 Review CO-OP approach, practice, homework. Session 3 Review CO-OP approach, plan outing, homework. Session 4 Review CO-OP approach, experiential learning according to participants' alternate COPM goals, homework. Session 5 Review CO-OP approach, outing, homework. Session 6 Review CO-OP approach, focus group, lessons learned, final COPM, homework
Study: NCT01856543

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eucerin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate 0.1%
Study: NCT01180712

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mirtoselect
Description: Male subjects (BMI \> 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given either a total daily dose of 1.4 grams of concentrated blaeberry extract (mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/) in a hard gelatin capsules or control capsules containing lactose administered thrice a day for 21 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mirtoselect
Description: Male subjects (BMI \> 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given either a total daily dose of 1.4 grams of concentrated blaeberry extract (mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/) in a hard gelatin capsules or control capsules containing lactose administered thrice a day for 21 days.
Study: NCT02989207

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: The current standard surgical treatment for glaucoma remains trabeculectomy. Wound healing modulation with antifibrotic agents, like MMC and 5-fluorouracil (5-FU), has been shown to increase the success of glaucoma filtering surgery in high-risk eyes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baerveldt tube surgery
Description: All glaucoma drainage devices consist of a tube which is inserted into the anterior chamber of the eye, draining aqueous humour to a plate which maintains a minimum bleb size and allows the collection of aqueous humour to be absorbed into the surrounding tissue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baerveldt tube surgery
Description: All glaucoma drainage devices consist of a tube which is inserted into the anterior chamber of the eye, draining aqueous humour to a plate which maintains a minimum bleb size and allows the collection of aqueous humour to be absorbed into the surrounding tissue.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitomycin-C
Description: This is an anti scarring agent whcih is an standard adjunctive treatment in glaucoma surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitomycin-C
Description: This is an anti scarring agent whcih is an standard adjunctive treatment in glaucoma surgery
Study: NCT03212625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea Cream 20%
Description: Sorafenib 400mg (twice daily), Spread urea cream (urea 20%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Sorafenib 400mg (twice daily), Spread placebo cream (urea 0%)
Study: NCT03619421

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc supplement
Description: 25 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc supplement
Description: 25 mg
Study: NCT02188485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENGAGE
Description: Up to 10 sessions delivered in the home.
Study: NCT04341974

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum creatinine
Description: Will be described: 1) the number of patients actually screened with postoperative serum creatinine and 2) the number of patients actually screened with the same parameter at the long-term after surgery
Study: NCT04043195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg every 2 weeks. Nivolumab will continue for up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles
Study: NCT04521491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).
Description: FOLFOX4 (OXA 85 mg/m2 intravenously \[IV\] on day 1; LV 200 mg/m2 IV from hour 0 to 2 on days 1 and 2; and FU 400 mg/m2 IV bolus at hour 2, then 600 mg/m2 over 22 hours on days 1 and 2, once every 2 weeks.All patients in the treatment group will receive FOLFOX4 at most 12 times beginning from the 4th week after liver resection.
Study: NCT03109678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crossover Ambu Aura-i™ / Rüsch Super Safety Silk™
Description: After unsuccessful blind intubation in the Ambu Aura-i™ / Rüsch Super Safety Silk™ group: crossover design using the Ambu Aura-i™ mask in combination with the LMA ETT™ tracheal tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crossover Ambu Aura-i™ / LMA ETT™
Description: After unsuccessful blind intubation in the Ambu Aura-i™ / LMA ETT group: crossover design using the Ambu Aura-i™ mask in combination with the Rüsch Super Safety Silk™ tracheal tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crossover FASTRACH™ / Rüsch Super Safety Silk™
Description: After unsuccessful blind intubation in the FASTRACH™ / Rüsch Super Safety Silk™ group: crossover design using the FASTRACH™ mask in combination with the LMA ETT™ tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crossover FASTRACH™ / LMA ETT™
Description: After unsuccessful blind intubation in the FASTRACH™ / LMA ETT™ group: crossover design using the FASTRACH™ mask in combination with the Rüsch Super Safety Silk™ tube
Study: NCT02667938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1303 capsule 5/0.2mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1303 capsule 5/0.4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP1201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP1303 capsule 5/0.2mg placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1303 capsule 5/0.2mg placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP1303 capsule 5/0.4mg placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1303 capsule 5/0.4mg placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1201 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1201 placebo